Health Canada is reviewing an application that seeks the approval of Trikafta, a triple combination reported to treat 90%…
Articles by Marisa Wexler, MS
A newly developed antibiotic, called T405, appears to effectively kill Mycobacteroides abscessus, a difficult-to-treat bacteria that can cause serious infections…
Children with cystic fibrosis (CF) who become infected with SARS-CoV-2 — the virus that causes COVID-19 — usually have…
Children with cystic fibrosis (CF) who are older, thinner, or have worse lung function may be at increased risk…
BiomX has unveiled a platform designed for more rapid and efficient development of phage therapy, which the company is…
A clinical trial testing AzurRx BioPharma‘s investigational therapy MS1819, in combination with the current standard care for the…
The Cystic Fibrosis Foundation (CFF) has awarded up to $3.3 million to Polyphor AG to advance the testing…
AzurRx BioPharma is requesting a new patient arm be added to its ongoing Phase 2b trial investigating MS1819 capsules as a…
The European Commission has approved Kalydeco (ivacaftor), by Vertex Pharmaceuticals, to treat infants as young as four months…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of…